Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI scanning. This collaboration will allow us to explore additional ways of commercializing our technology and could transform how MRI is used to diagnose cancer in the future.

Watch CEO Bob Proulx discuss the significance of the collaboration with the Market Herald: